Surrozen Announces Safety, Pharmacodynamic And Liver Function Data For SZN-043; Says Phase 1A Trial Demonstrated 'Acceptable' Safety And Tolerability With No Reported Serious Adverse Events
Surrozen Announces Safety, Pharmacodynamic And Liver Function Data For SZN-043; Says Phase 1A Trial Demonstrated 'Acceptable' Safety And Tolerability With No Reported Serious Adverse Events
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.